Kolinpharma S.p.A. (BIT:KIP) shareholders might be concerned after seeing the share price drop 13% in the last quarter. But that doesn’t change the reality that over twelve months the stock has done really well. Looking at the full year, the company has easily bested an index fund by gaining 42%.
Check out our latest analysis for Kolinpharma
Given that Kolinpharma didn’t make a profit in the last twelve months, we’ll focus on revenue growth to form a quick view of its business development. When a company doesn’t make profits, we’d generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.
In the last year Kolinpharma saw its revenue grow by 11%. That’s not great considering the company is losing money. The modest growth is probably largely reflected in the share price, which is up 42%. While not a huge gain tht seems pretty reasonable. It could be worth keeping an eye on this one, especially if growth accelerates.
The company’s revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
BIT:KIP Income Statement April 28th 2020
This free interactive report on Kolinpharma’s balance sheet strength is a great place to start, if you want to investigate the stock further.
A Different Perspective
It’s nice to see that Kolinpharma shareholders have gained 42% over the last year. We regret to report that the share price is down 13% over ninety days. It may simply be that the share price got ahead of itself, although there may have been fundamental developments that are weighing on it. It’s always interesting to track share price performance over the longer term. But to understand Kolinpharma better, we need to consider many other factors. For example, we’ve discovered 1 warning sign for Kolinpharma that you should be aware of before investing here.
But note: Kolinpharma may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on IT exchanges.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.